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Abstract
Background: Atovaquone is part of the antimalarial drug combination atovaquone-proguanil
(Malarone®) and inhibits the cytochrome bc1 complex of the electron transport chain in Plasmodium
spp. Molecular modelling showed that amino acid mutations are clustered around a putative
atovaquone-binding site resulting in a reduced binding affinity of atovaquone for plasmodial
cytochrome b, thus resulting in drug resistance.
Methods: The prevalence of cytochrome b point mutations possibly conferring atovaquone
resistance in Plasmodium falciparum isolates in atovaquone treatment-naïve patient cohorts from
Lambaréné, Gabon and from South Western Ethiopia was assessed.
Results: Four/40 (10%) mutant types (four different single polymorphisms, one leading to an amino
acid change from M to I in a single case) in Gabonese isolates, but all 141/141 isolates were wild
type in Ethiopia were found.
Conclusion: In the absence of drug pressure, spontaneous and possibly resistance-conferring
mutations are rare.
Background
The genetic complexity of Plasmodium falciparum and its
ability to generate mutant variants in particular makes it a
strikingly successful pathogen. Single nucleotide poly-
morphisms (SNPs) contribute largely to its genetic varia-
bility [1]. P. falciparum undergoes mutations in respective
target genes, thus resulting in variations of the encoded
proteins which facilitate escape from particular antimalar-
ial compounds.
The mitochondrion plays a functional key role in the elec-
tron transport system of the parasite [2]. By binding to the
cytochrome bc1 complex of the parasite, atovaquone,
which was introduced in a fixed combination with pro-
guanil hydrochloride as an antimalarial drug in the late
1990s [3], leads to the collapse of the mitochondrial
membrane potential at far lower concentrations than that
at which the respective mammalian system is affected
[4,5]. Its mode of action is unique in targeting parasite
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consumption [6] without affecting the host's mitochon-
drial functions [7]. In addition to electron transport inhi-
bition, atovaquone acts through destabilization of the
cytochrome bc1 complex, thus causing proton leakage to
occur through this site. Proguanil enhances this destabili-
zation [8,9].
Atovaquone has been a successful drug against several
eukaryotic microbial parasites [10], including Toxoplasma
gondii [11] and Pneumocystis carinii (now jirovecii) [12].
However, when used as a single agent against malaria, the
drug has shown a high rate of treatment failures [13,14].
Emergence of parasite resistance to atovaquone due to
point mutations in the cytochrome b gene has been
described [3] and confirmed in vitro and in vivo [15].
When used as a single agent, slow uptake and high
lipophilicity of the drug may result in a prolonged period
of parasite exposure to suboptimal atovaquone concen-
trations [8]. In consequence, atovaquone-resistant para-
sites appear to emerge frequently due to this suboptimal
therapy [13,14,16].
Due to the emergence of resistance against atovaquone as
a single therapeutic agent, inclusion of proguanil as a syn-
ergistic agent with atovaquone has been developed in
order to minimize the occurrence of drug resistance [17].
The combination of atovaquone and proguanil (Malar-
one®) has been found to be effective in treating malaria
[13]. While proguanil by itself had no effect on electron
transport or mitochondrial membrane potential, it signif-
icantly enhanced atovaquone efficacy when used in com-
bination [7,8].
Proguanil, in its prodrug form, acts in synergy with
atovaquone by lowering the effective concentration at
which atovaquone leads to a collapse of the mitochon-
drial membrane potential in malaria parasites. The net
result is a much lower incidence of treatment failure and
resistance emergence, as it has been observed in clinical
trials [8]. However, mutant strains of P. falciparum were
also resistant to the synergistic effects of atovaquone/pro-
guanil combination [7].
Atovaquone/proguanil is in use as an effective, safe and
acceptable prophylaxis and oral treatment for uncompli-
cated malaria in adults and children [18-23]. As it has
been already proposed as first-line therapy in Africa [24],
the background mutation rate in an area of Eastern and
Western Africa (Ethiopia and Gabon) where atovaquone/
proguanil has not been widely used outside of treatment
studies was determined in this study [25].
Materials and methods
The clinical material stemmed from clinical studies at
both study sites, and ethical approval was obtained from
the respective Ethics Committees of Addis Ababa Univer-
sity and of the International Foundation of the Albert Sch-
weitzer Hospital (HAS). Samples from the Ethiopian site
were collected at the Jimma Health Center from patients
with uncomplicated malaria as described earlier [26].
Forty other samples were collected at the HAS from
uncomplicated malaria cases in a study to validate low-
dose chemotherapy [27].
DNA analysis
The DNA extraction procedure was performed using QIA
amp® DNA Mini Kit (QIAGEN, Hilden, Germany), accord-
ing to the manufacturer's instruction. The samples were
analysed using nested PCR and DNA sequencing to detect
variation in the cyt b gene.
To obtain information about mutations in the cytochrome
b gene we analysed 40 parasite samples from Lambaréné,
Gabon. From these samples, the primers Cytb1 (5'-CTC-
TATTAATTTAGTTAAAGCACAC-3') and Cytb4 (5'-ACA-
GAATAATCTCTAGCACC-3') were used to amplify a
fragment of 939 bp containing the cyt b gene. The
obtained fragments were analysed on a 1% agarose gel for
purity. Gels were stained with CYBR® GREEN I nucleic acid
gel stain (Cambrex Bioscience, East Rutherford, NJ, USA)
and visualized on a dark reader transilluminator (Clare
Chemical Research, Dolores, CO, USA). Prior to sequenc-
ing, the amplified DNA was purified by a PCR purification
kit (E.Z.N.A.® Cycle – Pure Kit, Erlangen, Germany) fol-
lowing the supplier's instructions. Then, the DNA
sequence was determined using Big Dye 1.1® (Applied
Biosystems, Foster City, CA, USA) and purified again by
DNA grade Sephadex® (Amersham Biosciences AB, Upp-
sala Sweden). Strand separation was done on an Applied
Biosystems Genetic Analyzer 3100 (Foster City, CA, USA).
DNA sequences were finally analysed with the Bio-edit
sequence alignment program [28] to detect point muta-
tion.
141 samples from Ethiopia were subjected to PCR using
the primers CytbF (5'-GGGTATGATACAGCAT-
TAAAAATAC-3') and Cytb4 resulting in a 349 bp frag-
ment. Here we were interested only in the 3' end of the
gene since no mutations were detected in the 5' end in the
Gabonese samples. The samples were prepared as
described above.
Results and discussion
No mutations were detected in the Ethiopian samples.
Single nucleotide polymorphisms (one in each of 4 sam-
ples): T676A, C689T; T760G and G925T were detected in
the Gabonese samples. Only the latter exchange resultsPage 2 of 5
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were no mutations detected in codon 268.
The antimalarial activity of atovaquone and its enhancer
proguanil has been assessed in in vivo and in vitro drug
sensitivity tests, as well as in genetic studies in different
countries. In a study from Vietnam, it has been reported
that the combination of atovaquone with proguanil (AP)
yielded an overall cure rate of 86% to treat recrudescent P.
falciparum infections that had occurred after primary treat-
ment with other antimalarials. In their study, the authors
recommended AP as a safe and promising alternative
treatment for P. falciparum infections in South-East Asia
[29].
In another study, it was described that atovaquone has
shown better in vitro response as compared to other eight
antimalarials among the P. falciparum strains collected
from 14 countries in South and Central Africa. It was sug-
gested in the same study that atovaquone has a potential
to be used as an alternative antimalarial in Africa better
than Asian countries [30].
As with other antimalarials, concern about rapid emer-
gence of drug-resistant strains arose following initial
reports of definite, or possible, resistance-conferring poly-
morphisms of the cytochrome b gene found in treatment-
failing P. falciparum.
Mutations (Tyr268Asn and Tyr268Ser) of the P. falciparum
cytochrome b gene were reported in cases of malarone treat-
ment failure [15,31]. Sequencing of the cytochrome b-
encoding region of mitochondrial DNA together with
DNA samples from P. falciparum control strains yielded a
change from TAT to AAT in codon 268 (Y268N), specify-
ing a change from tyrosine (Tyr) to asparagine (Asn) in an
isolate from a Nigerian patient clinically (R1) and in vitro
resistant to atovaquone/proguanil [31].
A different mutation in this codon (TAT to TCT in codon
268) specifying a change from tyrosine to serine: Y268S
was found in a Thai patient with acute atovaquone and
pyrimethamine treatment failure [15], and it was also sug-
gested that a change of Tyr268 (Tyr) to Ser268 (Ser) may
be a sufficient cause for atovaquone/proguanil treatment
failure [32]. Therefore, mutations at codon 268 of the par-
asite cytochrome bc1 gene have been recognized as poten-
tial markers to measure and control the emergence of
resistance against atovaquone/proguanil treatment [33].
Further single or double amino acid mutations were gen-
erated from a cloned line exposed to various atovaquone
concentrations in vitro and leading to a significant reduc-
tion in parasite susceptibility to atovaquone. These muta-
tions are M133I, K272R, P275T, and G280D [15]. Thus,
multiple mutations in the cytochrome b gene are assumed
to be more useful in surveillance for atovaquone resist-
ance. Methods that can pick up multiple mutations (such
as DNA sequencing) will be appropriate for screening
[34]. However, in vivo atovaquone resistance may not
always be associated with previously identified cytochrome
b gene point mutations [35] since failure in drug action
can also be resulting from metabolic diversion to the alter-
native respiratory pathway of the parasite [36].
Sequencing of the cytochrome b gene of P. falciparum
from a patient returning from Mali with Malarone® treat-
ment failure revealed a point mutation at codon 268
(Tyr268Ser). However, there was no detection of altera-
tions at codon 133 of the strains which showed in vivo
treatment failure even though it has been found, in the
same study, in all strains that showed atovaquone resist-
ance in vitro [33].
These results underline that in the absence of drug pres-
sure, spontaneous and possibly resistance-conferring
mutations are rare. Assessing the activity of atovaquone
using in vitro drug sensitivity assay and DNA sequencing
of the cytochrome b gene, Basco and colleagues (2003)
did not report any mutations in the target gene in the P.
falciparum isolates collected from 37 Cameroonians [37].
In addition, using a low nanomolar range of atovaquone,
none of the isolates displayed any evidence for
atovaquone resistance in vitro. In another study, the com-
monly associated cytochrome b codon 268 mutation has
been assessed in 100 isolates of P. falciparum from North-
ern Ghana. None of these isolates exhibited mutation at
this position [38]. Pimentel et al. (2006) [39] studied
blood samples from 249 atovaquone-proguanil treat-
ment-naïve children and found a prevalence of possibly
resistance-conferring polymorphisms in codon 268 in a
frequency of < 0.77% (99% significance level).
A low prevalence of Ser268 (0.96%) and Asn268 (0.77%)
was also reported in other imported isolates of P. falci-
parum in Europe [32].
Single nucleotide polymorphisms occurred in the
Gabonese samples in four of the forty samples (T676A,
C689T, T760G, G925T), of which only one led to an
amino acid change which has not been associated before
with resistance in vitro and/or in vivo, and which may well
not be resistance-conferring. No mutations were detected
in the isolates from Ethiopia. This is consistent with those
of previous studies from various African countries [37,38].
Musset et al. (2006) [40] genotyped 477 atovaquone-
unexposed African P. falciparum isolates and found exclu-
sively wild types. Berry et al. (2006) [41] found polymor-
phisms in 12/135 (8.9%) of unexposed West and Central
African isolates; an overall rate which is consistent withPage 3 of 5
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only three led to transversions with amino acid changes;
again, a rate very to the one presented in this paper.
Conclusion
In the absence of drug pressure, spontaneous and possibly
resistance-conferring mutations are rare. In line with the
findings presented here, an elevated rate of resistance
against atovaquone is not reported in most of similar
studies in endemic areas and in the absence of drug pres-
sure. However, a higher rate of resistance in the future is
likely to occur under drug pressure [16,32,36]. As this
would be in accordance with the experience with amino-
quinoline and sulpha drugs, possibly, probably and defi-
nitely resistance-confirming polymorphisms (single, or in
combination) will occur with almost certainty.
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